Using SGLT2 Inhibitors in Patients With T1DM: PRO
What is the background of using SGLT2 Inhibitors and why we may consider using them in patients with T1DM?
Are there particular patients in whom you would consider SGLT2 inhibitors in addition to traditional insulin therapy?
What is the increased risk of ketoacidosis in patients that will start SGLT2 inhibitors?
What are some advantages of SGLT2 inhibitors if you consider another therapy, for example amylin?
Synthetic Hydrogels as Engineered Niches in Regenerative Medicine
What are synthetic hydrogels?
How can hydrogels be useful in the context of endocrine disorders?
What are some of the obstacles in bringing synthetic hydrogels in human trials?
What are the potential applications in regenerative medicine?
How Much Surveillance Is Too Much?
What are the take home message of your presentation?
What clinical parameters are used to classify patients as disease-free?
Can you tell us about active surveillance?
How can one define the optimal surveillance strategy?
Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline
Can you tell us about the new Endocrine Society Clinical Practice Guidelines for lipid management and how they are different from previous versions?
Can you tell us about new approaches and therapies?
What about other endocrine disorders that we should be paying attention to in terms of lipid management?
Are there any guidelines with respect to younger patients?
Are there specific targets?
Early Follow-up of Atypical Thyroiditis Induced by SARS-CoV-2
Can you tell us about your study?
Do you think this could be a manifestation of a direct viral infection of the thyroid?
Did these patients have other laboratory evidence of subacute thyroiditis?
What are the perspectives of therapy for these patients?
Using SGLT2 Inhibitors in Patients With T1DM: CON
What is the rationale for using SGLT2 inhibitors in patients with T1DM?
What is the experience in countries where SGLT2 inhibitors have been approved for use?
“High Risk” Features of Differentiated Thyroid Cancer Are Commonly Found in Autopsy Studies: Implications for the ATA Guidelines
What is the background of your study and what you found?
What are the current practice guidelines for high risk features?
How do you think it would change clinical practice?
Is there any way to make any of these diagnoses prior to surgery and improve diagnostic capabilities?
What Pediatric Endocrinologists Need to Know About Dyslipidemia
What are some of the common lipid disorders in pediatric patients?
Are there specific clinical features that will cause you to screen for lipid disorders?
What is the prevalence of FH hypercholesterolemia in children?
Is there a role for lifestyle changes in pediatric patients with lipid disorders?